<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 1539 from Anon (session_user_id: 073bbd17ca2d151a9e138c177f9e9cf6991506f3)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 1539 from Anon (session_user_id: 073bbd17ca2d151a9e138c177f9e9cf6991506f3)</h1>
    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><p style="text-align:justify;">In normal cells, CpG islands are hypomethylated or unmethylated but the genome, in general, are methylated in repetitive elements, intergenic region and, also, in the introns of genes. This methylation pattern is intended silencing gene expression. However, in cancer cell, the methylation pattern is reversed: CpG islands are likely to be methylated but intergenic region, the repetitive elements and also the introns are hypomethylated.</p>
<p style="text-align:justify;">In general, the methylation of the CpGs islands found in cancer (CpG island hypermethylation) are located in the promoters of tumour suppressor genes and is associated with silencing of this genes. Moreover, in cancer cell often CpG islands of a set of genes are frequently methylated (CpG island methylator phenotype), and more recently has been discovered that <span style="font-size:14px;line-height:21px;">CpG island shores are </span><span style="font-size:14px;line-height:21px;">hypermethylated in cancer too. What's more, in cancer is also found h</span><span style="font-size:14px;line-height:21px;">ypermethylation of ICRs which leads to loss of imprinting and it is known that a</span><span style="font-size:14px;line-height:21px;">lterations in DNA methylation at ICRs both hypo or </span><span style="font-size:14px;line-height:21px;">hypermethylation, can result in loss of expression of growth </span><span style="font-size:14px;line-height:21px;">restricting genes and overexpression of growth promoting genes.</span></p>
<p style="text-align:justify;"><span style="font-size:14px;line-height:21px;">On the other hand, genome-wide hypomethylation is also an abnormality found in cancer cells wich c</span><span style="font-size:14px;line-height:21px;">onsequences depend on </span><span style="font-size:14px;line-height:21px;">location. If hypomethylation occurs in intergenic regions o repetitions, it leads to genomic instability. Although if hypomethylation takes place in CpG poor promoters, it leads to a oncogene activation.</span></p>
<p style="text-align:justify;"><span style="font-size:14px;line-height:21px;">To sum up, DNA methylation in cancer leads to hypomethylation genome-wide and tumour suppreson hypermethylation. Finally, </span><span style="font-size:14px;line-height:21px;">is important to point out that the role of DNA methylation is context dependent both in normal cell and cancer. </span></p>
<p> </p></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><p><span>In cancer cell is common to find h</span><span>ypermethylation of Imprint Control Regions (ICRs) which leads to loss of imprinting. It is known that a</span><span>lterations in DNA methylation at ICRs </span><span>can result in loss of expression of growth </span><span>restricting genes and overexpression of growth promoting genes. </span>In the H19/Igf2 cluster <span style="font-size:14px;line-height:21px;">the ICRs </span><span style="font-size:14px;line-height:21px;">it's methylated on the paternal </span><span style="font-size:14px;line-height:21px;">allele, but it's unmethylated on the </span><span style="font-size:14px;line-height:21px;">maternal allele, w</span><span style="font-size:14px;line-height:21px;">hen CTCF 4 bind is </span><span style="font-size:14px;line-height:21px;">insulator element, so the </span><span style="font-size:14px;line-height:21px;">enhancers will act on H19, b</span><span style="font-size:14px;line-height:21px;">ut Igf2 will be silent for the maternal </span><span style="font-size:14px;line-height:21px;">allele. However, o</span><span style="font-size:14px;line-height:21px;">n the paternal allele (</span><span style="font-size:14px;line-height:21px;">methylated) the enhancers c</span><span style="font-size:14px;line-height:21px;">an act on IGF2, because CTCF is not </span><span style="font-size:14px;line-height:21px;">binding to insulate this, and IGF2 is </span><span style="font-size:14px;line-height:21px;">expressed from the paternal allele. </span></p>
<p><span style="font-size:14px;line-height:21px;">In cancer cell, with loss of imprinting, there is a </span><span style="font-size:14px;line-height:21px;">high hypermethylation </span><span style="font-size:14px;line-height:21px;">of the ICRs on the </span><span style="font-size:14px;line-height:21px;">maternal allele as well. </span><span style="font-size:14px;line-height:21px;">Now, on the maternal allele, </span><span style="font-size:14px;line-height:21px;">you </span><span style="font-size:14px;line-height:21px;">have a double dose of Igf2 in </span><span style="font-size:14px;line-height:21px;">comparison to what you have in a normal </span><span style="font-size:14px;line-height:21px;">cell.  </span><span style="font-size:14px;line-height:21px;">And Igf2 is both growth promoting, and </span><span style="font-size:14px;line-height:21px;">this is associated with Wilm's tumor, a</span><span style="font-size:14px;line-height:21px;"> childhood kidney tumor.</span></p>
<p><span style="font-size:14px;line-height:21px;">In conclusion, loss of imprinting </span><span style="font-size:14px;line-height:21px;">is observed in a very wide array of tumor </span><span style="font-size:14px;line-height:21px;">types, and</span><span style="font-size:14px;line-height:21px;"> occurs </span><span style="font-size:14px;line-height:21px;">in </span><span style="font-size:14px;line-height:21px;">preneoplastic tissues. This example </span><span style="font-size:14px;line-height:21px;">suggests that maybe these methylation </span><span style="font-size:14px;line-height:21px;">events at the imprint control region m</span><span style="font-size:14px;line-height:21px;">ight be very early events in tumor</span><span style="font-size:14px;line-height:21px;">genesis.</span></p>
<p> </p></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><p><span style="font-size:14px;line-height:21px;">Decitabine is an epigenetic drug, specifically a</span><span style="font-size:14px;line-height:21px;"> DNA methyltransferase inhibitor (DNMT) are used to treat myelodysplastic syndromes, the precursors of acute myelogenous leukaemia.  </span><span style="font-size:14px;line-height:21px;">They are nucleoside analogues, so they get incorporated into the DNA </span><span style="font-size:14px;line-height:21px;">upon replication, and then, when the DNA </span><span style="font-size:14px;line-height:21px;">methyltransferase comes along to bind </span><span style="font-size:14px;line-height:21px;"> that </span><span style="font-size:14px;line-height:21px;">nucleotide to then copy the methylation </span><span style="font-size:14px;line-height:21px;">to the daughter strand, that DNA </span><span style="font-size:14px;line-height:21px;">methyltransferase is bound irreversibly </span><span style="font-size:14px;line-height:21px;">and it can no longer be released. </span><span style="font-size:14px;line-height:21px;">And this means that the action of these </span><span style="font-size:14px;line-height:21px;">DNA methyltransferase inhibitors is therefore </span><span style="font-size:14px;line-height:21px;">division dependent. </span><span style="font-size:14px;line-height:21px;">So this means that cancer cells which are </span><span style="font-size:14px;line-height:21px;">dividing much more rapidly than most </span><span style="font-size:14px;line-height:21px;">other cells in the body will be more </span><span style="font-size:14px;line-height:21px;">severely affected because they're </span><span style="font-size:14px;line-height:21px;">replicating more. </span></p>
<p> </p></div>

    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><p>Altering DNA methylation can have enduring effects on the epigenome. For example, due to the lack of specificity inherent to the mechanism of action of DNA methyltransferase inhibitors that causes long term effects on normal cells. This effects can be increased if the treatment with DMNTs are in sensitive periods,<span style="font-size:14px;line-height:21px;"> when altered environments have an effect on epigenetic control. This periods take place </span><span style="font-size:14px;line-height:21px;">during embryogenesis and </span><span style="font-size:14px;line-height:21px;">gametogenesis, when marks are established rather </span><span style="font-size:14px;line-height:21px;">than maintained. Also there is a s</span><span style="font-size:14px;line-height:21px;">ensitive period for food supply is “slow growth period”: </span><span style="font-size:14px;line-height:21px;">9-12 years in grandfathers, </span><span style="font-size:14px;line-height:21px;">8-10 years in grandmothers, plus</span><span style="font-size:14px;line-height:21px;"> fetal/ infant life for grandmothers. </span><span style="font-size:14px;line-height:21px;">Alterations on DNA methylation could pass across generation if affects germ cells in younger patients or other sensitive periods, which leads to have</span><span style="font-size:14px;line-height:21px;"> enduring effects on the epigenoma.</span></p>
<p><span style="font-size:14px;line-height:21px;"><br /></span></p>
<p><span style="font-size:14px;line-height:21px;"><br /></span></p></div>
  </body>
</html>